South Korea Neurology Clinical Trials Market Report 2022 to 2030

South Korea Neurology Clinical Trials Market Analysis

$ 3999

The South Korea Neurology Clinical Trials market is projected to grow from $76.4 Mn in 2022 to $126.5 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022 - 2030. The market will be driven by the supportive regulatory environment and increasing interest from pharmaceutical companies investing in neurology clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Hoffmann-La Roche, Biogen & Chong Kun Dang Pharmaceutical.

ID: IN10KRCT005 CATEGORY: Clinical Trials GEOGRAPHY: South Korea AUTHOR: Vidhi Upadhyay

Buy Now

South Korea Neurology Clinical Trials Market Executive Summary

The South Korea Neurology Clinical Trials market is projected to grow from $76.4 Mn in 2022 to $126.5 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022 - 2030. In 2020, South Korea had 799 authorised clinical trials for drug treatments, 432 of which were local trials and the remainder were global. The number of both local and global trials grew over the previous year. Korea is one of the world's fastest ageing nations, and the rising incidence of dementia will place a significant strain on Korean society. For example, by 2050, the old-age dependency ratio is expected to rise from 20% to about 70%.

Alzheimer's disease is an increasing problem around the globe, including in South Korea. Numerous South Korean research institutions and pharmaceutical businesses are now focusing on creating novel Alzheimer's disease therapies. Patients with mild cognitive impairment, early-stage Alzheimer's disease, or mild to moderate Alzheimer's disease may be included in clinical trials for novel Alzheimer's medications. Moreover, In South Korea, several clinical trials are ongoing to investigate new therapies for Parkinson's disease, such as deep brain stimulation, gene therapy, and stem cell therapy. Seoul National University, Asan Medical Center, Samsung Medical Center, and Yonsei University Severance are four of the top ten worldwide clinical investigator sites. The country's combination of clinical trial competence, superior healthcare infrastructure, large population concentration, and a very receptive, investment-minded administration has propelled the country to the forefront of clinical trial venues globally.

South Korea Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

South Korea boasts a comprehensive medical system that is outfitted with cutting-edge equipment and facilities. This infrastructure facilitates clinical trial conduct by giving access to specialised equipment and medical staff. South Korea has a huge number of qualified medical workers, including physicians, nurses, and researchers who have received clinical trial training. South Korea's regulatory procedure is streamlined, fast, and transparent, making it an appealing place for conducting clinical trials. The South Korean government has aggressively promoted the expansion of clinical trials in the nation. The Ministry of Food and Drug Safety has built a framework to promote the research and approval of novel pharmaceuticals and medical devices. Pharmaceutical firms are highly keen on carrying out clinical trials in South Korea. The country's superior medical infrastructure, qualified workforce, and supportive regulatory framework are driving this interest.

Market Restraints

South Korea has a population of about 51 million people, which is very little compared to other nations. This restricted patient pool may make recruiting enough participants for clinical trials difficult, especially for uncommon or complicated neurological illnesses. Although much medical personnel in South Korea know English, some patients may choose to participate in clinical studies performed in their native language. This may reduce the number of people who are eligible to participate in clinical studies. Other nations in the area, like China and Japan, are also substantially investing in clinical research. South Korea may find it difficult to recruit clinical trials and investment as a result of this competition. Although the regulatory climate in South Korea is typically supportive of clinical trials, regulatory hurdles may nevertheless impede the clearance process. Although the South Korean government supports clinical research, financing for clinical trials remains low, especially for uncommon disorders. This may make it difficult for researchers to undertake the studies required to bring novel therapies to market.

Competitive Landscape

Key Players

Hoffmann-La Roche
Biogen
Chong Kun Dang Pharmaceutical (KOR)
SK Biopharmaceuticals
Merck
AstraZeneca
Janssen
Daewoong Pharmaceutical (KOR)
Novo Nordisk
AbbVie
Hanmi Pharmaceutical (KOR)

Notable Deals

January 2023, Daewoong Pharmaceutical Co., a renowned South Korean pharmaceutical, announced a collaboration agreement with Oncorus Inc., a biotech business based in the United States, to develop and commercialise messenger RNA (mRNA) therapeutics for cancer patients.

August 2021, Novartis announced the termination of a partial clinical trial hold and the launch of a new pivotal Phase 3 investigation of intrathecal OAV-101 in elderly SMA patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.